CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 92 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $7,568 | -99.9% | 1,295,833 | -2.6% | 0.41% | -17.3% |
| Q3 2022 | $8,914,000 | +50.0% | 1,330,433 | -5.7% | 0.50% | +60.6% |
| Q2 2022 | $5,941,000 | +33.8% | 1,411,153 | +7.1% | 0.31% | +56.6% |
| Q1 2022 | $4,440,000 | +3.7% | 1,317,423 | -3.0% | 0.20% | +2.6% |
| Q4 2021 | $4,280,000 | -25.3% | 1,358,573 | -22.5% | 0.19% | -26.3% |
| Q3 2021 | $5,732,000 | -21.4% | 1,752,904 | +1.4% | 0.26% | -19.1% |
| Q2 2021 | $7,296,000 | +0.6% | 1,728,900 | +18.9% | 0.32% | -4.4% |
| Q1 2021 | $7,255,000 | -57.9% | 1,453,975 | +6.7% | 0.34% | -60.1% |
| Q4 2020 | $17,218,000 | +28.6% | 1,362,203 | -0.1% | 0.85% | -7.5% |
| Q3 2020 | $13,391,000 | -2.6% | 1,363,603 | -1.3% | 0.92% | +16.3% |
| Q2 2020 | $13,751,000 | +6.9% | 1,382,048 | -5.1% | 0.79% | -8.9% |
| Q1 2020 | $12,869,000 | -4.8% | 1,455,812 | -0.7% | 0.87% | +18.4% |
| Q4 2019 | $13,521,000 | +50.1% | 1,465,712 | -4.3% | 0.73% | +66.4% |
| Q3 2019 | $9,007,000 | -44.8% | 1,531,862 | +12.7% | 0.44% | -43.9% |
| Q2 2019 | $16,313,000 | +14.6% | 1,359,375 | +15.3% | 0.78% | +15.8% |
| Q1 2019 | $14,230,000 | -4.0% | 1,178,975 | -0.2% | 0.68% | -13.3% |
| Q4 2018 | $14,821,000 | -25.6% | 1,180,975 | -12.1% | 0.78% | -6.9% |
| Q3 2018 | $19,930,000 | -11.5% | 1,342,975 | +0.4% | 0.84% | -19.6% |
| Q2 2018 | $22,516,000 | -25.6% | 1,337,862 | +1.2% | 1.04% | -29.2% |
| Q1 2018 | $30,275,000 | -11.0% | 1,322,062 | +0.6% | 1.48% | -5.6% |
| Q4 2017 | $34,008,000 | +90.7% | 1,314,562 | +8.7% | 1.56% | +68.5% |
| Q3 2017 | $17,834,000 | +21.1% | 1,209,062 | +14.5% | 0.93% | +16.1% |
| Q2 2017 | $14,731,000 | -18.2% | 1,056,000 | 0.0% | 0.80% | -16.8% |
| Q1 2017 | $18,015,000 | +63.9% | 1,056,000 | -1.2% | 0.96% | +60.4% |
| Q4 2016 | $10,993,000 | +21.5% | 1,068,300 | +19.4% | 0.60% | +18.8% |
| Q3 2016 | $9,045,000 | +29.0% | 894,687 | +43.3% | 0.50% | +21.7% |
| Q2 2016 | $7,013,000 | – | 624,500 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |